UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Study suggests CD4+ T cells mediate these immune-related toxicities ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the importance of long-term monitoring. A recent study reveals CAR T-cell therapy ...

CAR T-cell therapies achieve high response rates in relapsed/refractory MCL but have severe toxicities and complex manufacturing processes. Bispecific antibodies offer logistical advantages and ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that go after a range of tumors while avoiding patients' healthy tissue. The ...

A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that could put some pressure on CAR T-cell therapies, including the company’s own ...